News74

Platform delivers genetic/genomic data directly into the EHR workflow for Epic customers

Raleigh, NC – Nov. 3, 2021 – 2bPrecise™ announced its Precision Health™ platform is now available in the Epic App Orchard Gallery. The App Orchard program enables developers to integrate their healthcare IT solutions with the Epic electronic health record (EHR) using standards-based APIs.

The 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs. It synthesizes these elements into a clinical-genomic ontology and brings the resulting insights into the provider’s workflow to support timely clinical decisions at the point of care. The solution is built to interact with evolving knowledge sources and care guidelines to deliver the most up-to-date insights to providers.

“We established 2bPrecise to make precision medicine a reality by offering providers easy access to the genomic data and relevant insights for smarter, better and faster care decisions tailored to each individual patient,” said 2bPrecise CEO Assaf Halevy. “To bring genomic insights to the point of care, we need to create a seamless process for providers, regardless of the EHR and information systems they had in place. By joining the App Orchard, we’re able to bring enhanced genomic insights directly to Epic users within their workflow, making it easier for them to make informed care decisions in real-time.”

The 2bPrecise platform has been recognized for healthcare innovation by multiple industry organizations, such as FierceHealthcare, Microsoft and MedTech Breakthrough. All Epic community members can now explore and access the award-winning Precision Health platform in the App Orchard gallery.

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more.

Epic and App Orchard are trademarks of Epic Systems Corporation.

Media Contact:

Elizabeth Coleman
Account Coordinator
Aria Marketing (for 2bPrecise)
(231) 313-8974
ecoleman@ariamarketing.com

Combined capabilities create industry’s most advanced precision medicine enablement solution

PITTSBURGH and HOUSTON – Aug. 25, 2021 – AccessDX Holdings, an international provider of advanced laboratory diagnostic solutions, has acquired 2bPrecise™ from Allscripts Healthcare Solutions. A recognized leader and innovator in healthcare informatics, 2bPrecise enables organizations to amplify their precision medicine strategies by delivering point-of-care insights so providers can identify patients at risk for heritable conditions, arrive at precise diagnoses more quickly and initiate optimal therapies more quickly.

2bPrecise will join the AccessDX portfolio of industry-leading diagnostics, software and services, including the MedTek21 software platform which facilitates diagnostic-based clinical decision support, compliance and program analytics for thousands of care organizations, patient groups and providers. The combined strengths of AccessDX and 2bPrecise ensure meaningful insights will be accessible within the clinical workflow of any EHR, while helping organizations streamline virtually all aspects of establishing and supporting precision medicine programs.

“We’re thrilled to welcome the 2bPrecise team and platform as we execute on our combined vision for democratizing the use, interpretation and delivery of advanced diagnostic solutions at the point of care,” said Joe Spinelli, SVP of Product & Strategy for AccessDX. “Combined, our worldwide organization will be able to accelerate the pace of innovation and best serve the needs of healthcare organizations that continue to expand their adoption of actionable precision medicine solutions.”

Utilization of genetic and genomic data is accelerating across nearly all clinical specialties, perhaps most notably in behavioral health/psychiatry, neonatology and pediatrics, oncology and cardiology. Providers can arrive at precise diagnoses faster and initiate effective treatments sooner when genetic and genomic information is available and actionable. Providers, payers and clinical organizations alike agree that the ability to seamlessly access information within their clinical workflow is key to precision-medicine success.

“AccessDX is a genuine leader in genomic information management. Our collective capabilities will serve as a force multiple for the practical utilization of precision medicine,” said Assaf Halevy, founder and CEO of 2bPrecise. “With a unified mission to drive dimensional change in healthcare, the combined talents and energy of 2bPrecise and AccessDX will compound acceleration in delivering on our vision of intelligent, personalized care for the good of healthcare organizations and the patients they serve.”

About AccessDX Laboratory

AccessDX Laboratory is a CLIA-certified, CAP-accredited and NYCQ diagnostic laboratory dedicated to providing clinical insights that improve patient outcomes. AccessDX diagnostic solutions include COVID- 19 testing, pharmacogenomic (PGX) testing, cancer genomic (CGX) testing, respiratory pathogen panels and a wide range of other clinical laboratory services. AccessDX diagnostic and software solutions are currently trusted by thousands of clinical providers in health systems nationwide. For more information, please visit www.AccessDXlab.com.

About MedTek21

MedTek21 is a real-time population health and medication risk management platform that brings personalized drug-to-gene monitoring to every patient. The company’s software-based platform works alongside existing medical record systems to continuously monitor, proactively identify, and help remediate potential medication risks. MedTek21’s mobile-based medication risk alerting, drug lookup tools, actionable reporting, and clinical support staff enable both patients and their care providers with better real-time decision making. MedTek21 is being used to positively impact outcomes and lower care costs for tens of thousands of patients across general, acute, and chronic populations. For more information on the MedTek21, please visit www.MedTek21.com.

About 2bPrecise

The 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. It brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are equipped to drive efficient workflows for genomic workflows and decision-making, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. www.2bPreciseHealth.com.

Media Contact:

Emily Wisner
Account Executive, Aria Marketing (for 2bPrecise)
ewisner@ariamarketing.com
224-392-6352

Summer 2021 product features customer-driven enhancements, including patient-directed family history documentation, and strengthens infrastructure for greater scalability

RALIEGH, NC – July 27, 2021 – 2bPrecise, an EHR-agnostic, cloud-based precision medicine platform, announced it delivered advanced and innovative functionality to clients via its Summer 2021 Product Release.

With market adoption of genetic and genomic testing accelerating, 2bPrecise added new tools and features to support point-of-care decision making for providers across a wide range of clinical specialties. Primary among the enhancements are risk stratification algorithms that help providers identify patients at greatest potential risk for drug-gene interactions, specifically those taking five or more medications. New automation notifies providers if any of their patients’ medications carries pharmacogenomic (PGx) indicators and prompts them to consider pharmacogenomic testing.

“An astounding number of individuals – 20% of Americans aged 40-79 – take five or more medications,” said Assaf Halevy, CEO and founder of 2bPrecise. “This cohort is at great risk for drug-gene interactions. 2bPrecise now helps these patients’ clinicians quickly identify who should undergo PGx testing to improve medication safety and ensure patients are on the most effective drug based on their unique genetic profile.” He added that 2bPrecise’s polypharmacy risk identification also represents a logical and manageable starting point for organizations unsure of how to initiate their PGx programs or identify which patients to prioritize.

The Summer 2021 release likewise makes a beta version of the 2bPrecise Precision Timeline available to new and existing clients. Precision Timeline is an at-a-glance summary view of the patient journey, presented visually instead of in narrative form, with the ability to click into specific documents, medications and molecular results. The current version of the feature focuses on oncology, but it can also be adapted for additional clinical use cases such maternal fetal medicine and pediatrics. Displaying a cross-domain, chronological view over time, Precision Timeline enables providers to instantly comprehend the patient story without examining dozens of screens and documents in the electronic health record (EHR).

“We received enthusiastic feedback from clients about Precision Timeline,” Halevy noted. “It will save clinicians significant time as they review the patient journey over time and spanning multiple providers. Clinicians can more easily prepare for appointments and tumor board sessions. Plus, they can be more confident as they have a comprehensive view of the patient’s status and condition to support clinical decision making.”

Patient engagement and enablement are also critical components to this 2bPrecise upgrade. Patients using the FollowMyHealth® portal will be able to complete family history documentation at their own convenience, outside of office visits. The information will populate the 2bPrecise pedigree module automatically, saving genetic counselors and other clinicians significant time as they evaluate which patients are at risk for heritable diseases and should be referred for genetic testing.

Additional enhancements include user-friendly attributes of the Genomic EHR Mentor (GEM™) application that resides on the users native EHR desktop, as well as improved platform infrastructure for optimal security and performance.

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.

###

Media Contact:
Erica Navar
Account Executive, Social Media Manager
Aria Marketing for 2bPrecise
(909) 538-9541

Partnership will enable member orthopedic surgeons to identify potential drug-gene interactions to improve the patient experience and outcomes

RALEIGH, N.C. and LAKE FOREST, Calif. – May 24, 2021 – US Orthopedic Alliance (USOA) has selected 2bPrecise to provide its precision medicine platform to USOA’s network of more than 100 orthopedic surgeons. The 2bPrecise pharmacogenomics module initially will be rolled out to four member practices over the coming months, equipping USOA physicians with the ability to effectively identify potentially dangerous drug-gene interactions so that patients receive the safest, most effective care possible.

“We recognize that precision medicine represents a new standard in health care,” said Rick Salas, CEO of USOA. “We’re committed to delivering the services, technologies and infrastructure orthopedic surgeons need so they can factor patient genetic profiles into their diagnostic and treatment decisions. It truly is a win for both the patient and the provider.” Providers offering precision medicine programs often achieve a competitive advantage over other practices in their service areas, he adds.

The 2bPrecise platform will deliver workflow, data management and clinical decision functionality to USOA providers ordering pharmacogenomic tests (PGx). Specifically, doctors can leverage test results to make informed decisions about powerful pain medications, anticoagulants, antiemetics or other drugs they may prescribe for patients.

Salas continued, “Core to our mission is a commitment to providing orthopedists with specialty-specific services to manage and grow their practices while enhancing the patient experience. Physician members benefit from USOA’s business intelligence solutions, including revenue cycle management, contracting, risk management and value-based care services such as infrastructure, technology and data analytics.”

“We are delighted to work with USOA to bring precision medicine and other genomic insights into the orthopedic workflow”, said Assaf Halevy, CEO and co-founder of 2bPrecise. “USOA has demonstrated its strong leadership in this area and is committed to ensuring its physician members are successful while improving the health and lives of patients. Together, we will help accelerate a dimensional change in how safe orthopedic care is delivered.”

Please visit 2bPrecise Pharmacogenomics about learn more about the extensive value of PGx for more information.

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.

About US Orthopedic Alliance

With deep expertise in health information technology and practice management, USOA is a management services organization that provides its network of physicians, group practices, ambulatory surgery centers, and specialty surgery hospitals with a full suite of services that enable growth and achieve operational efficiencies. For more information on USOA, please visit www.usorthopedicalliance.com.

Media Contacts:
Erica Navar
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com

Andrew Meehan
Meehan Business Advisers (for USOA)
(949) 285-0759
ameehan@meehanba.com

Leader in precision medicine solutions and multispecialty clinic customer to discuss the promise of genetic data at the point of care

RALIEGH, NC – May 17, 2021 – 2bPrecise, a leader in precision medicine solutions, will present on the value of pharmacogenomics (PGx) at the AMIA 2021 Clinical Informatics Conference. The company will be joined by longtime customer Murfreesboro Medical Clinic and SurgiCenter (MMC) for the virtual presentation, “Quantitative and Qualitative Outcomes Using IT-Supported Pharmacogenomics at the Point of Care.” Together, 2bPrecise and MMC will explore ways health IT tools and PGx testing can improve medication safety, reduce adverse drug events and accelerate therapeutic value for patients.

“Pharmacogenomics, or how drugs interact with a patient’s genes, is incredibly valuable when it comes to determining the best medication for a patient,” said Dr. Joel Diamond, a practicing physician at Handelsman Family Practice in Pittsburgh, PA and chief medical officer at 2bPrecise. “Genetic profiles can eliminate trial-and-error prescribing by ensuring medications are safe and effective from the outset. As an organization on the forefront of precision medicine, we are thrilled to showcase at AMIA and share now MMC is leveraging our tools to better understand a patient’s genetic data and provide better care.”

Dr. Diamond and MMC Chief Medical Informatics Officer and President Dr. Nicholas Cote will draw from their successful implementations of PGx programs to explore the role IT plays in giving providers better insight into patients’ genetic data to help inform clinical decisions. The duo will also discuss the obstacles commonly encountered when initiating point-of-care precision medicine programs, lessons learned and best practices from implementing these programs within their own practices, and measurable outcomes the organizations have experienced.

“Leveraging genetic data to identify how patients will metabolize certain medications is a critical step in ensuring patients receive high-value care,” said Dr. Cote. “Powerful precision medicine solutions can give providers the necessary support to make care decisions with certainty. We look forward to presenting at AMIA and sharing our successes and real-world experiences with colleagues who might be considering similar programs.”

Drs. Diamond and Cote’s session, “Quantitative and Qualitative Outcomes Using IT-Supported Pharmacogenomics at the Point of Care,” will take place virtually Thursday, May 20, 2021 from 1:00–2:00 PM ET.

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract
population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable
participation in research studies and more.

Media Contact:
Erica Navar
Account Executive
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com

Prestigious Award Recognizes Outstanding Health and Medical Technology Products and Companies

RALEIGH, N.C., – May 11, 2021 – 2bPrecise, a leader in precision medicine solutions, today announced it has once again been selected as the winner of the “Best Overall Genomics Solution” award in the fifth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.

The cloud-based 2bPrecise platform delivers precision medicine insights to providers within their familiar workflow, across any electronic health record (EHR). The solution is built to interact with ever-evolving genetic/genomic knowledge sources and care guidelines, and is integrated as part of the complete compendium of patient information. This actionable data set helps drive better diagnoses and faster treatment.

Among its many functions, the platform optimizes manual, document-driven processes and deliver a consolidated view of patient genetic/genomic results within the clinical context. It works to simplify workflows and connect care teams across the enterprise – providers, genetic counselors, pathologists, pharmacists and more. Additionally, 2bPrecise delivers a consistent clinical experience across the organization when providers leverage genomics, no matter which EHR they use. Lastly, the platform enables leadership to govern clinical practice around genetic/genomic testing for greater efficiency and value.

“2bPrecise delivers a smart technology infrastructure that not only supports genomic data management today, but provides in-workflow access to valuable informational resources far into the future,” said James Johnson, managing director, MedTech Breakthrough. “2bPrecise delivers a breakthrough platform for scalable precision medicine and we are thrilled to extend our congratulations to the 2bPrecise team for its back-to-back ‘Best Overall Genomics Solution’ award win.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including robotics, clinical administration, telehealth, patient engagement, EHR, mHealth, medical devices, medical data and many more. This year’s program attracted more than 3,850 nominations from 17-plus countries throughout the world.

“Genomics is redefining the standard of care and we’re working with a wide variety of clients to help them build an informatics strategy to power transformative point-of-care solutions,” said Assaf Halevy, founder and CEO, 2bPrecise. “We’re honored to receive this 2021 MedTech Breakthrough Award again, and look forward to continued success and momentum as we drive innovation in precision medicine.”

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more.

About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is an independent program devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.

Winter 2021 release features advanced patient timeline to improve cancer care and analytics to identify patients at greatest risk for adverse drug reactions

RALIEGH, NC – March 31, 2021 – 2bPrecise delivers advanced and innovative functionality to clients via its winter 2021 product release this month.

Responding to rising market demands for improved access to genetic and genomic insights to support clinical decisions, 2bPrecise added features enabling oncologists to view a contextualized “patient journey” so they can more easily understand optimal next steps in diagnosis and treatment. Expanded access to pharmacogenomic (PGx) knowledgebases and analytic services likewise help providers across all clinical specialties select drugs that deliver the best therapeutic outcome with fewest side effects.

“The 2bPrecise platform was developed to make sure clinicians could use the full potential of genetic and genomic information as they make care decisions,” said 2bPrecise CEO and cofounder Assaf Halevy. “Precision medicine is powering a dimensional shift in how healthcare providers diagnose and treat disease. With these latest innovations, we aim to accelerate opportunities for providers to integrate genetic information at the point of care within their familiar workflow.”

Among the notable functionality featured in the 2bPrecise winter 2021 release are:

• • Introduction of an innovative 2bPrecise™ Precision Timeline, enabling clients to access previous tests, diagnoses, labs and notes in a single view to eliminate time-consuming “document hunting” during clinical decision-making;
  • PGx candidate identification support to determine patient cohorts at greatest risk for drug-gene interactions (especially in those taking multiple medications);
    Broader PGx knowledgebases to incorporate the latest medication ontologies and scientific discoveries;
  • Additional lab integrations to enhance insights from tumor test results (somatic), including identification of additional biomarkers and chromosomal alterations;
  • Functionality that allows clinicians to easily search for negative genetic/genomic findings to easily determine if a specific condition or genotype was covered by an ordered test

“We are grateful for the trust our clients have shown to us, and appreciate the feedback that made these enhancements possible,” noted Halevy. The winter 2021 release was rolled out to existing 2bPrecise clients this month and all features will be available to new clients going forward.

About 2bPrecise
The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract
population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable
participation in research studies and more. Learn more at www.2bPreciseHealth.com.

Media Contact:
Erica Navar
Account Executive
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com

Texas provider to focus on oncology initially, then expand across specialties and care settings

RALEIGH, NC, and ABILENE, TX – Dec. 16, 2020 – Hendrick Health will deploy the 2bPrecise platform as the foundation for its precision medicine program. The initial focus will be in cancer care, where a significant volume of genomic testing is already being done, with enterprise-wide utilization to follow.

Located three hours west of Dallas, Hendrick is the flagship healthcare provider for mid-west Texas. Anchored by Hendrick Medical Center in Abilene, the health system offers a full range of care including oncology, cardiology, orthopedics and women’s health, with nearly 1,000 healthcare providers on staff. Other facilities include Hendrick Medical Center South in Abilene and Hendrick Medical Center Brownwood in Brownwood.

“Our entire team is committed to innovation and personalized care,” says Jose Vega, MD, Medical Director of Hendrick Cancer Center. “Precision medicine will help us improve quality, outcomes and patient wellbeing. It provides unprecedented opportunities to arrive at more accurate diagnoses and select highly effective targeted therapies, as well as to more easily identify patients at risk for inherited disease.”

With Hendrick Health’s initial focus on cancer care, the 2bPrecise solution will deliver results from tumor genomic testing (somatic information) to help oncologists identify the treatment most likely to produce optimal results based on the molecular profile of the malignant tissue. If they choose, providers likewise can use pharmacogenomic testing to help identify the safest and most effective medications for each individual patient, as well as view information suspected to represent germline variations that may indicate the patient or family members would benefit from further genetic testing.

2bPrecise is designed to solve workflow and data management challenges faced by healthcare organizations implementing precision medicine. Genomic test results typically are returned to the physician in a PDF or require logging in to the testing lab’s proprietary portal. This makes the information inconvenient to access and, because it is not saved as discrete data, difficult to analyze and use more broadly. In addition, physicians will have fingertip access to evidence-based clinical guidelines and current knowledge resources to support decision making.

“It’s critical to bring this data into the clinician’s workflow, with no extra steps, so the insights can be factored into clinical decision making,” says Dr. Vega. “This allows our team to deliver better and more efficient care.”

Agnostic to various laboratory information systems and electronic health records (EHR), 2bPrecise will consume genomic data from Hendrick’s chosen labs (LabCorp, ARUP and NeoGenomics) and deliver it within the organization’s EHR, Allscripts Sunrise™.

“We’re honored to work with the leaders and clinicians at Hendrick Health,” said 2bPrecise CEO Assaf Halevy. “Their perspective on the value precision medicine delivers is tightly aligned with ours, and we look forward to collaborating to help Hendrick Health deliver outstanding care to patients.”

About 2bPrecise
The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.

Media Contact
Erica Navar
Account Executive
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com

Pittsburgh physicians seek to improve medication safety, efficacy for patients

RALIEGH, NC – December 3, 2020 – Handelsman Family Practice, which provides care to patients in southeast Pittsburgh, has implemented the 2bPrecise pharmacogenomics (PGx) solution. The solution makes patient genomic information available to providers at the point of care, so they can ensure medications they prescribe are safe for each individual and are the ones most likely to provide fast therapeutic benefit.

According to Gordon Handelsman, MD, owner and practice medical director, PGx gives providers greater insight into how each patient’s body will process specific drugs. “Traditionally, physicians have had to use the ‘trial-and-error’ method of selecting medications,” he says. “Based on the patient’s diagnosis, you would choose the drug you thought most likely to be effective, based on broad-based clinical trials or information provided by a drug rep. You had no way to be sure it would be best option for the individual sitting in front of you.”

That led to providers prescribing one drug, waiting to see if it worked, then altering the dosage or moving on to a second option. This process could repeat itself over weeks or months, with no relief in sight for the patient. This prolonged approach has especially serious consequences for patients with conditions like depression or high cholesterol, among others.

With PGx results brought into the clinicians’ workflow via 2bPrecise, providers can see if the patient is a fast, normal or slow metabolizer of a given medication, which has a tremendous impact on safety and efficacy. For example, patients who have suffered a heart attack are often prescribe clopidogrel (e.g., Plavix) to prevent blood clots and ward off a second cardiac event. Fast metabolizers, however, process clopidogrel so quickly that it provides almost no therapeutic value – meaning it does little more than a placebo to avert a second heart attack. In slow metabolizers, the drug builds up in the patient’s body, likewise interfering with the intended benefit and potentially leading to toxicity.

“Having this knowledge in hand is particularly helpful when we care for elderly patients taking multiple medications,” Dr. Handelsman added. “Drug-gene interactions can contribute to avoidable problems such as the likelihood of falling and cognitive issues like confusion – in addition to not adequately treating the underlying condition.” He also notes that providing this level of service and innovation has a positive impact on patient satisfaction and loyalty.

Availability of in-workflow PGx functionality has also helped the practice weather challenges during the COVID-19 pandemic. Providers are able to discuss PGx with patients during a telehealth visit and, with consent, the patient can do the PGx test (a simple cheek swab) in their own home. The follow-up visit to discuss results can likewise be conducted via telehealth.

“2bPrecise has seen a dramatic increase in family medicine practices seeking to leverage genomics,” says Assaf Halevy, CEO and cofounder of 2bPrecise. “PGx is a terrific starting point to demonstrate how precision medicine can impact day-to-day and patient-by-patient decision making. We’re honored to work with innovators like Dr. Handelsman and his care team.”

About 2bPrecise
The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.

Media Contact
Erica Navar
Account Executive
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com

Leading Bay-area ENT group to launch precision medicine program, beginning with pharmacogenomics

RALEIGH, NC—Nov. 11, 2020—San Francisco Otolaryngology has selected the 2bPrecise™ platform as the foundation for its precision medicine strategy, beginning with pharmacogenomics (PGx) and potentially expanding to additional genetic/genomic testing.

According to Jacob Johnson, MD, president of the medical group, the practice’s initial focus will be to introduce PGx to a cohort of patients participating in a multidisciplinary clinical program addressing issues related to aging. “Our interest in precision medicine focuses on general patient wellness. We find the drugs patients take have an important effect on the main variables we assess: whether they are able to exercise, are cognitively intact, engage in social interaction and are safe from falling,” he explains.

“My colleagues and I believe strongly in bringing innovative answers to our patients as we help them maintain and improve their health. Pharmacogenomic results will help us select the right medications for each patient, with assurance that they are also the safest and least likely to cause side effects or adverse reactions.”
With five locations, SF Otolaryngology has delivered comprehensive care for sinus, thyroid and other ear/nose/throat (ENT) conditions since 1940. Its physicians also hold academic appointments at University of California, San Francisco.

2bPrecise consumes genetic/genomic data from molecular labs and clinical information from EHRs. It synthesizes these elements into a clinical-genomic ontology and brings the resulting insights into the provider’s workflow to support timely clinical decisions.

In selecting 2bPrecise, SF Otolaryngology saw an opportunity to apply the benefits of genomic science in a practical setting, beyond the academic medical community. “Most patients, after all, are treated within their own communities,” said Dr. Johnson. “We want to ensure they have access to best clinical practices and the most innovative approaches to their care.” A pilot PGx program is underway at the practice, with roll out across all patients planned for the new year.

“We are gratified that San Francisco Otolaryngology has placed its trust in our platform,” says Assaf Halevy, president and CEO of 2bPrecise. “Precision medicine represents an exciting ‘new horizon’ for healthcare, and San Francisco Otolaryngology leadership has embraced genomics as a strategy to improve its patients’ experience and wellbeing. We’re excited to get started and to see where our partnership takes us.”

About 2bPrecise
The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract
population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.

Media Contact
Erica Navar
Account Executive
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com